MENLO PARK, Calif., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced that Thomas W. Chalberg, Jr., Ph.D., Founder and Chief Executive Officer, will present at two upcoming investor conferences:
- Cowen and Company 35th Annual Health Care Conference on Wednesday, March 4, 2015 at 8:40 a.m. EST in Boston.
- Barclays Global Healthcare Conference on Tuesday, March 10, 2015 at 2:30 p.m. EDT in Miami, FL.
Live webcasts of the presentations will be accessible under Events & Presentations in the Investors section of Avalanche's website. Avalanche will maintain an archived replay of the webcasts on its website for two weeks after each conference.
About Avalanche Biotechnologies, Inc.
Avalanche is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. Avalanche's lead product, AVA-101, is currently under development in a Phase 2a trial for wet age-related macular degeneration. Avalanche's Ocular BioFactory™ platform technology is a proprietary adeno-associated virus (AAV)-based gene therapy discovery and development technology optimized for ophthalmology that utilizes a directed evolution approach to generate novel drug candidates. For more information, please visit www.avalanchebiotech.com.
CONTACT: Media and Investor Contact Susan Neath Francis (212) 301-7182 firstname.lastname@example.org
Source:Avalanche Biotechnologies, Inc.